Advertisement

Document › Details
CRISPR Therapeutics AG. (10/2/18). "Press Release: CRISPR Therapeutics to Present at the Chardan Genetic Medicines Conference". Zug & Cambridge, MA.
![]() |
Region | New York, NY |
Country | United States (USA) | |
![]() |
Organisation | CRISPR Therapeutics AG (Nasdaq: CRSP) |
Group | CRISPR Therapeutics (Group) | |
Organisation 2 | Chardan Capital Markets LLC | |
![]() |
Product | Chardan Genetic Medicines Conference 2018 New York |
Product 2 | CRISPR gene editing technology | |
![]() |
Index term | CRISPR Therapeutics–Chardan: investor conference, 201810 supply service CRISPR presents at Chardan Genetic Medicines Conference in New York |
![]() |
Person | Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO) |
Person 2 | Kim, Susan (CRISPR Therapeutics 201809 Investor Relations) | |
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer, will present at the Chardan Genetic Medicines Conference on Tuesday, October 9, 2018 at 11:30 am ET.
A live webcast of the Chardan presentation will be available on the "Events & Presentations" page in the Investors section of the company's website at https://crisprtx.com/events. A replay of the webcast will be archived on the company's website for 14 days following the presentation.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG, Vertex Pharmaceuticals and ViaCyte, Inc.
CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.
CRISPR Investor Contact:
Susan Kim
susan.kim@crisprtx.com
CRISPR Media Contact:
Jennifer Paganelli
WCG on behalf of CRISPR
347-658-8290
jpaganelli@wcgworld.com
Record changed: 2018-10-13 |
Advertisement

More documents for CRISPR Therapeutics (Group)
- [1] CRISPR Therapeutics AG. (10/28/20). "Press Release: CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results". Zug & Cambridge, MA....
- [2] CRISPR Therapeutics AG. (6/30/20). "Press Release: CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares". Zug & Cambridge, MA....
- [3] CRISPR Therapeutics AG. (6/29/20). "Press Release: CRISPR Therapeutics Announces Proposed Offering of Common Shares". Zug & Cambridge, MA....
- [4] CRISPR Therapeutics AG. (6/25/20). "Press Release: CRISPR Therapeutics Announces the Build-Out of New Cell Therapy Manufacturing Facility". Zug & Cambridge, MA....
- [5] CRISPR Therapeutics AG. (5/11/20). "Press Release: CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001 for the Treatment of Severe Hemoglobinopathies". Zug, Cambridge, MA...
- [6] CRISPR Therapeutics AG. (5/7/20). "Press Release: CRISPR Therapeutics to Present at the Bank of America Securities 2020 Health Care Conference". Zug & Cambridge, MA....
- [7] CRISPR Therapeutics AG. (2/26/20). "Press Release: CRISPR Therapeutics Proposes Changes to the Board of Directors". Zug & Cambridge, MA....
- [8] CRISPR Therapeutics AG. (2/12/20). "Press Release: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results". Zug & Cambridge, MA....
- [9] CRISPR Therapeutics AG. (11/20/19). "Press Release: CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares". Zug & Cambridge, MA....
- [10] CRISPR Therapeutics AG. (11/19/19). "Press Release: CRISPR Therapeutics Announces Proposed Public Offering of Common Shares". Zug & Cambridge, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement
![Picture [iito] Made Without Love 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-made-without-love.jpg)
» top